Table 1.
Demographic and baseline characteristics of the patients (n = 30)
|
Characteristics
|
|
|
| Sex—No. of patients (%) | ||
| Male | 18.0 | (60.0) |
| Female | 12.0 | (40.0) |
| Age (years)1 | 48.8 | (13.6) |
| Weight (kg)1 | 55.9 | (11.1) |
| TSAT (%)2 | 39.6 | (23.0) |
| Ferritin (ng/mL)2 | 931.2 | (592.7) |
| Hemoglobin (g/dL)1 | 7.4 | (1.3) |
| Hematocrit (%)1 | 22.2 | (4.0) |
| Reticulocyte count (%)1 | 1.1 | (0.9) |
| eGFR (ml/min/1.73 m2 | 6.2 | (3.3) |
| BUN (mg%)2 | 77.1 | (34.2) |
| Creatinine (mg%)2 | 10.0 | (4.5) |
| Albumin (g%)2 | 3.8 | (0.6) |
| Vitamin B12 (pg/mL)2,4 | 922.3 | (422.9) |
| Folic acid (ng/mL)2,4 | ||
| RBC folate (n = 19) | 8192.8 | (4785.0) |
| Serum folate (n = 10) | 102.2 | (217.4) |
| C-reactive protein (mg/L)2 | 10.7 | (29.5) |
All data were presented as mean (standard deviation), unless otherwise stated.
1
Data from screening visit.
2
Data from Week 0 prior to study drug initiation.
3
Data were calculated using chronic kidney disease epidemiology collaboration formula[13].
4
Data available in 29 patients. BUN: Blood urea nitrogen; eGFR: Estimated glomerular filtration rate; RBC: Red blood cell; TSAT: Transferrin saturation.